Combination of mitomycin, vindesine, and cisplatin in the treatment of head and neck squamous cell carcinoma

Détails

ID Serval
serval:BIB_F431806F8FF6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Combination of mitomycin, vindesine, and cisplatin in the treatment of head and neck squamous cell carcinoma
Périodique
Cancer Treatment Reports
Auteur(s)
Leyvraz  S., Barrelet  L., Savary  M., Bernasconi  S.
ISSN
0027-8874
0361-5960 (Print)
Statut éditorial
Publié
Date de publication
01/1987
Volume
71
Numéro
1
Pages
81-2
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jan
Résumé
Thirty patients with squamous cell carcinoma of the head and neck were treated with a combination of mitomycin (10 mg/m2, Day 1), vindesine (3 mg/m2, Days 1 and 8), and cisplatin (60 mg/m2, Day 1), repeated every 28 days. Seven patients were previously treated by surgery, radiotherapy, or chemotherapy, and 23 had untreated advanced tumors. Objective responses were seen in 17 of 27 evaluable patients (63%), with three (11%) complete remissions. Moderate myelosuppression was the main toxic effect. Considering the advanced tumor staging (54% N3 tumors), this chemotherapeutic regimen appears as effective as other cisplatin-based chemotherapies.
Mots-clé
Adult Aged Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Carcinoma, Squamous Cell/*drug therapy Cisplatin/administration & dosage Drug Evaluation Female Head and Neck Neoplasms/*drug therapy Humans Male Middle Aged Mitomycins/administration & dosage Vindesine/administration & dosage
Pubmed
Web of science
Création de la notice
28/01/2008 9:31
Dernière modification de la notice
03/03/2018 22:43
Données d'usage